UNSPSC 51172158: Alverine citrate

This classification denotes an antispasmotic agent and anticholinergic agent with the molecular formula C20H27N.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9JFB58YK1E, chemically known as n,n-bis(3-phenylpropyl)ethylamine but more generally known as alverine citrate, which bears US NIH Compound Identifier 3678. European Medicines Agency schedules Alverine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00421MIG.

Most nations, for tariff and trade purposes, schedule alverine citrate under HS 29214980 and SITC 51454. As of Q4 2014, ALVERINE CITRATE remains US FDA's Preferred Term for this commodity. Alverine citrate bears US NLM NCI C72692. SMILES: CCN(CCCC1CCCCC1)CCCC2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51172158 Alverine citrate (Commodity) shows minimal alignment with recent state and local procurement activity. The code nominally describes a pharmaceutical compound used as an antispasmodic agent, but the single recent opportunity posted under this code — Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services — involves no procurement of alverine citrate itself. Instead, the county is soliciting comprehensive urinalysis and alternative drug-screening services, including specimen collection at two sites (Plano and McKinney), immunoassay screening with confirmatory testing via LC/MS/MS or GC/MS, oral fluid and hair testing, and electronic result reporting. The issuing body is a county corrections and supervision department, not a health system or medical supplier typically purchasing pharmaceutical products.

The mismatch between the code's nominal scope and the actual procurement suggests either a coding error in the source or that alverine citrate procurement under this code does not currently surface in state and local contract notices. Collin County's RFP 2026-327, with an estimated contract value of $600,000 and a response deadline of July 23, 2026, is structured as a two-year term with three optional one-year renewals, evaluated on compliance, vendor qualifications, client references, and cost. Without additional recent opportunities under this code in the source, no reliable geographic pattern or issuing-body mix can be characterized. A business development professional should verify whether this code truly reflects pharmaceutical purchases at the state and local level or represents a classification mismatch requiring clarification from the procuring jurisdiction.